Provided by Tiger Trade Technology Pte. Ltd.

Stoke Therapeutics, Inc.

25.62
-0.3900-1.50%
Post-market: 25.620.00000.00%19:30 EDT
Volume:848.62K
Turnover:21.88M
Market Cap:1.65B
PE:-7.69
High:26.46
Open:26.46
Low:25.45
Close:26.01
52wk High:40.22
52wk Low:20.32
Shares:64.53M
Float Shares:49.01M
Volume Ratio:0.61
T/O Rate:1.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3325
EPS(LYR):-0.1163
ROE:-61.10%
ROA:-35.87%
PB:4.78
PE(LYR):-220.36

Loading ...

Stoke Therapeutics Names Thomas Mccauley Chief Scientific Officer

Reuters
·
Jul 13

Stoke Therapeutics Appoints Thomas Mccauley, Ph.d., as Chief Scientific Officer

THOMSON REUTERS
·
Jul 13

Stoke Therapeutics Initiated at Buy by Goldman Sachs

Dow Jones
·
Jul 13

Stoke Therapeutics initiated with a Buy at Goldman Sachs

TIPRANKS
·
Jul 13

Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?

Simply Wall St.
·
Jul 10

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)

TIPRANKS
·
Jul 09

Stoke Therapeutics CMO Barry Ticho Disposes of Common Shares Worth $235,889.32

Reuters
·
Jul 07

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 06

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Reuters
·
Jul 06

Stoke Therapeutics (STOK) Receives a Buy from Jefferies

TIPRANKS
·
Jul 02

Stoke Therapeutics Completes Enrollment in Phase 3 Emperor Trial of Dravet Drug Zorevunersen

Reuters
·
Jun 30

Stoke Therapeutics - no Patients Have Discontinued Treatment in Phase 3 Emperor Study

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics - Phase 3 Data Readout Anticipated in Q3 2027, to Complete Nda Submission in H2 2027

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients into the Phase 3 Emperor Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

THOMSON REUTERS
·
Jun 30

Stoke Therapeutics - Plans to Initiate Rolling U.S. Nda Submission to FDA in Q1 2027

THOMSON REUTERS
·
Jun 30

Does Broad Russell Index Removal Reshape the Bull Case for Stoke Therapeutics (STOK)?

Simply Wall St.
·
Jun 29

Stoke Therapeutics General Counsel Jonathan Allan sells $43,638.15 in common shares

Reuters
·
Jun 19

Stoke Therapeutics grants options for 103,020 shares to nine new employees at $30 each

Reuters
·
Jun 17

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 17

Stoke Therapeutics (STOK) Gets a Buy from Leerink Partners

TIPRANKS
·
Jun 05